Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04876079
Other study ID # 2022-1119
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2021
Est. completion date June 30, 2023

Study information

Verified date August 2023
Source Institut de Recherches Cliniques de Montreal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose < 4.0 mmol/L), 15-20g of rapidly absorbed carbohydrates should be ingested. Patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. These recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy. In practice, only 32-50% of patients follow the current guidelines. In addition, recent studies suggest that under current intensive insulin therapies, an initial correction with 15g of oral glucose may be insufficient to rapidly correct mild-to-moderate hypoglycemia. With the development and increasing usage of newer glucose monitoring technologies, the community is witnessing a shift in hypoglycemia management, from a reactive to a proactive approach (e.g., prevent imminent episodes rather than treating established episodes).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 30, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males and females = 18 years old 2. Clinical diagnosis of type 1 diabetes for at least one year 3. Treatment with multiple daily insulin injections or insulin pump therapy with insulin analogs (rapid, ultra-rapid and basal insulin) 4. A glycated hemoglobin A1c = 10% Exclusion Criteria: 1. Clinically significant microvascular complications: nephropathy (eGFR < 40 ml/min), severe proliferative retinopathy as judged by the investigator, neuropathy (particularly diagnosed gastroparesis) 2. Recent (< 3 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery) 3. Known significant cardiac rhythm abnormality based on investigator's judgement 4. Known significant neurological abnormality (e.g., seizure disorder) based on investigator's judgement 5. Ongoing pregnancy or breastfeeding 6. Severe hypoglycemia episode within 1 month of screening 7. Known uncorrected hypokalemia within the past 3 months (potassium < 3.5 mmol/L)

Study Design


Intervention

Other:
Test to induce a decline in plasma glucose
Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
Device:
Dexcom G6
Participants will have to wear a Dexcom G6 during study interventions
Other:
Dex4
When the glycemic threshold is reach, participants will be given 16g of Dex4
Drug:
Insulin
A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.

Locations

Country Name City State
Canada Montreal Clinical Research Institute Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Institut de Recherches Cliniques de Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time spent of glucose levels < 4.0 mmol/L 60 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 5 minutes after carbohydrates consumption 5 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 10 minutes after carbohydrates consumption 10 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 15 minutes after carbohydrates consumption 15 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 20 minutes after carbohydrates consumption 20 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 30 minutes after carbohydrates consumption 30 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 45 minutes after carbohydrates consumption 45 minutes after carbohydrates consumption
Secondary Plasma glucose levels at 60 minutes after carbohydrates consumption 60 minutes after carbohydrates consumption
Secondary Lowest plasma glucose level eached after CHO consumption 60 minutes after carbohydrates consumption
Secondary Time from CHO consumption to the lowest plasma glucose level reached 60 minutes after carbohydrates consumption
Secondary Time from CHO consumption to plasma glucose < 3.5 mmol/L 60 minutes after carbohydrates consumption
Secondary Percentage of participants reaching hypoglycemia (< 4.0 mmol/L) after CHO consumption 60 minutes after carbohydrates consumption
Secondary Percentage of participants for whom hypoglycemia was corrected at 10 minutes after CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 10 minutes after carbohydrates consumption
Secondary Percentage of participants for whom hypoglycemia was corrected at 15 minutes after CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 15 minutes after carbohydrates consumption
Secondary Percentage of participants for whom hypoglycemia was corrected at 20 minutes after CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 20 minutes after carbohydrates consumption
Secondary Percentage of participants for whom hypoglycemia was corrected at 25 minutes after CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 25 minutes after carbohydrates consumption
Secondary Percentage of participants for whom hypoglycemia was corrected at 30 minutes after CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 30 minutes after carbohydrates consumption
Secondary Percentage of participants for whom hypoglycemia was corrected at 35 minutes after CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 35 minutes after carbohydrates consumption
Secondary Percentage of hypoglycemic events that were corrected at 10 minutes after CHO consumption Only calculated for events with glucose level < 4.0 mmol/L 10 minutes after carbohydrates consumption
Secondary Percentage of hypoglycemic events that were corrected at 15 minutes after CHO consumption Only calculated for events with glucose level < 4.0 mmol/L 15 minutes after carbohydrates consumption
Secondary Percentage of hypoglycemic events that were corrected at 20 minutes after CHO consumption Only calculated for events with glucose level < 4.0 mmol/L 20 minutes after carbohydrates consumption
Secondary Percentage of hypoglycemic events that were corrected at 25 minutes after CHO consumption Only calculated for events with glucose level < 4.0 mmol/L 25 minutes after carbohydrates consumption
Secondary Percentage of hypoglycemic events that were corrected at 30 minutes after CHO consumption Only calculated for events with glucose level < 4.0 mmol/L 30 minutes after carbohydrates consumption
Secondary Percentage of hypoglycemic events that were corrected at 35 minutes after CHO consumption Only calculated for events with glucose level < 4.0 mmol/L 35 minutes after carbohydrates consumption
Secondary Percentage of participants requiring a second treatment with carbohydrates at 20 minutes after the first CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 20 minutes after carbohydrates consumption
Secondary Percentage of participants requiring a second treatment with carbohydrates at 40 minutes after the first CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 40 minutes after carbohydrates consumption
Secondary Percentage of participants requiring a second treatment with carbohydrates at 60 minutes after the first CHO consumption Only calculated for participants who will have glucose levels < 4.0 mmol/L 60 minutes after carbohydrates consumption
Secondary Percentage of participants experiencing a rebound hyperglycemia (= 10.0 mmol/L) within the first hour following the first carbobydrates consumption 60 minutes after carbohydrates consumption
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4